Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | THOR: impact of FGFR3 alterations in mUC on subtype and outcomes with erdafitinib vs pembrolizumab

Arlene Siefker-Radtke, MD, discusses the findings from the Phase III THOR (NCT03390504) study evaluating erdafitinib, an oral pan-FGFR tyrosine kinase inhibitor, in patients with advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRalt). The study compared erdafitinib to pembrolizumab, showing that erdafitinib improved objective response and progression-free survival (PFS) but not overall survival (OS). Molecular analysis of the tumors revealed a significant proportion of the luminal-papillary subtype among FGFRalt tumors, which were associated with better response to erdafitinib. However, despite the benefits in response rates and PFS, these did not translate into an OS advantage. The University of Texas MD Anderson Cancer Center, Houston, TX. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.